系统性红斑狼疮患者传统心血管危险因素的患病率与达标情况:一项纳入24个国家3401例个体的横断面研究
这项多中心横断面研究收集24个国家2015年1月1日至2020年1月1日随访的3401例成人系统性红斑狼疮(SLE)患者资料,评估传统心血管危险因素患病率及达标情况。结果显示高血压、肥胖、高脂血症患病率较高,可改变危险因素控制欠佳;中高收入国家患者血压和血脂达标率低于高收入国家,合并抗磷脂综合征患者体质指数与血脂达标率更低。
要点
- SLE患者高血压患病率为35.6%、肥胖为23.7%、高脂血症为19.8%,可改变心血管危险因素控制欠佳。
- 高收入国家患者血压达标率54.9%、中收入国家46.8%,高收入国家较高(p<0.0001)。
- 合并抗磷脂综合征的SLE患者体质指数及低密度脂蛋白、非高密度脂蛋白达标率显著低于无抗磷脂综合征者。
核心结论
- 在大型多中心、多种族SLE队列中观察到传统心血管危险因素患病率高且控制不足,尤其中收入国家患者和合并抗磷脂综合征者。
- 作者认为迫切需要提高对SLE患者心血管疾病风险的认识,尤其是上述亚组。
研究设计与样本
- 多中心横断面研究,收集24个国家五大洲2015年1月1日至2020年1月1日随访的成人(年龄≥18岁)SLE患者病历中的心血管危险因素数据。
- 共纳入3401例SLE患者,中位年龄43.0岁(IQR 33-54);3396例中女性3047例(89.7%)、男性349例(10.3%);3390例中白人1629例(48.1%);2681例中合并抗磷脂综合征556例(20.7%)。
- 采用系统性冠状动脉风险评估算法估计心血管风险,并依据欧洲心脏病学会指南评估心血管危险因素达标情况。
主要发现
- 高血压1210/3398例(35.6%)、肥胖751/3169例(23.7%)、高脂血症650/3279例(19.8%)。
- 高收入国家与中收入国家比较:血压达标(<130/80 mm Hg)为54.9%(1170/2132例)vs 46.8%(519/1109例),p<0.0001。
- 高密度脂蛋白达标为75.0%(895/1194例)vs 51.4%(386/751例),p<0.0001;非高密度脂蛋白达标为66.4%(769/1158例)vs 60.8%(453/745例),p=0.013;甘油三酯达标为80.9%(1017/1257例)vs 61.4%(486/792例),p<0.0001。
- 合并抗磷脂综合征的SLE患者可改变心血管危险因素患病率更高,体质指数及低密度脂蛋白、非高密度脂蛋白达标率显著低于无抗磷脂综合征者。
关键数值与推荐
- 血压目标为<130/80 mm Hg,采用欧洲心脏病学会指南评估达标情况。
- 高收入国家血压达标54.9%(1170/2132例)vs 中收入国家46.8%(519/1109例),p<0.0001。
- 高密度脂蛋白达标75.0%(895/1194例)vs 51.4%(386/751例),p<0.0001;非高密度脂蛋白达标66.4%(769/1158例)vs 60.8%(453/745例),p=0.013;甘油三酯达标80.9%(1017/1257例)vs 61.4%(486/792例),p<0.0001。
临床怎么用
- 作者认为迫切需要提高对SLE患者心血管疾病风险的认识,尤其是中收入国家患者及合并抗磷脂综合征者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Systemic lupus erythematosus (SLE) is characterised by increased cardiovascular morbidity and mortality risk. We aimed to examine the prevalence of traditional cardiovascular risk factors and their control in an international survey of patients with systemic lupus erythematosus. METHODS: In this multicentre, cross-sectional study, cardiovascular risk factor data from medical files of adult patients (aged ≥18) with SLE followed between Jan 1, 2015, and Jan 1, 2020, were collected from 24 countries, across five continents. We assessed the prevalence and target attainment of cardiovascular risk factors and examined potential differences by country income level and antiphospholipid syndrome coexistence. We used the Systemic Coronary Risk Evaluation algorithm for cardiovascular risk estimation, and the European Society of Cardiology guidelines for assessing cardiovascular risk factor target attainment. People with lived experience were not involved in the research or writing process. FINDINGS: 3401 patients with SLE were included in the study. The median age was 43·0 years (IQR 33-54), 3047 (89·7%) of 3396 patients were women, 349 (10.3%) were men, and 1629 (48·1%) of 3390 were White. 556 (20·7%) of 2681 patients had concomitant antiphospholipid syndrome. We found a high cardiovascular risk factor prevalence (hypertension 1210 [35·6%] of 3398 patients, obesity 751 [23·7%] of 3169 patients, and hyperlipidaemia 650 [19·8%] of 3279 patients), and suboptimal control of modifiable cardiovascular risk factors (blood pressure [target of <130/80 mm Hg], BMI, and lipids) in the entire SLE group. Higher prevalence of cardiovascular risk factors but a better blood pressure (target of <130/80 mm Hg; 54·9% [1170 of 2132 patients] vs 46·8% [519 of 1109 patients]; p<0·0001), and lipid control (75·0% [895 of 1194 patients] vs 51·4% [386 of 751 patients], p<0·0001 for high-density lipoprotein [HDL]; 66·4% [769 of 1158 patients] vs 60·8% [453 of 745 patients], p=0·013 for non-HDL; 80·9% [1017 of 1257 patients] vs 61·4% [486 of 792 patients], p<0·0001 for triglycerides]) was observed in patients from high-income versus those from middle-income countries. Patients with SLE with antiphospholipid syndrome had a higher prevalence of modifiable cardiovascular risk factors, and significantly lower attainment of BMI and lipid targets (for low-density lipoprotein and non-HDL) than patients with SLE without antiphospholipid syndrome. INTERPRETATION: High prevalence and inadequate cardiovascular risk factor control were observed in a large multicentre and multiethnic SLE cohort, especially among patients from middle-income compared with high-income countries and among those with coexistent antiphospholipid syndrome. Increased awareness of cardiovascular disease risk in SLE, especially in the above subgroups, is urgently warranted. FUNDING: None.
引用
- Bolla E, Semb AG, Kerola AM, et al. Prevalence and target attainment of traditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countries. Lancet Rheumatol. 2024. PMID: 38878780. doi:10.1016/S2665-9913(24)00090-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。